Home > Insider Trading > Filing (0001562180-19-006296)

Filing Details

Accession Number:: 0001562180-19-006296
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-31 19:33:17
Reporting Period:: 2019-12-30

Accepted Time:: 2019-12-31 19:33:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1704483	Robert Berman	C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510	Special Projects & Med Ovrsght	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2019-12-30	125,000	$0.61	125,341	No	4	M	Direct
Common Shares	Disposition	2019-12-30	67,450	$52.95	57,891	No	4	S	Direct
Common Shares	Disposition	2019-12-30	53,762	$53.43	4,129	No	4	S	Direct
Common Shares	Disposition	2019-12-30	3,488	$54.89	641	No	4	S	Direct
Common Shares	Disposition	2019-12-30	300	$55.97	341	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (right to buy)	Disposition	2019-12-30	125,000	$0.00	125,000	$0.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
100,000		2024-11-25	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	550,000	Indirect	By Berman Family Trust 2013
Common Shares	240,500	Indirect	By Berman Marital Trust 2013
Common Shares	50	Indirect	Owned by Spouse

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.23 - $53.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.23 - $53.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.64 - $55.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The option, representing a right to purchase a total of 225,000 shares, was granted on November 26, 2014, and vested in four equal installments on November 26, 2014, 2015, 2016 and 2017